Ilaprazole
- Generic Name
- Ilaprazole
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18N4O2S
- CAS Number
- 172152-36-2
- Unique Ingredient Identifier
- 776Q6XX45J
- Background
Ilaprazole has been investigated in Helicobacter Infections.
- Indication
用于治疗十二指肠溃疡及反流性食管炎。
Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06725992
- Locations
- 🇰🇷
Chungbuk National University Hospital, Seoul, Seowon-gu, Korea, Republic of
Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
- Conditions
- Peptic Ulcer
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT06284876
- Locations
- 🇰🇷
Chung Ang University Hospital, Seoul, Korea, Republic of
A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding
- Conditions
- Stress Ulcer Bleeding
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Livzon Pharmaceutical Group Inc.
- Target Recruit Count
- 449
- Registration Number
- NCT05841394
- Locations
- 🇨🇳
Shanghai Jiaotong University Affiliate Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hopspital of Xinjiang Medical University, Urumchi, Xinjiang, China
Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05617651
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac
- Conditions
- Drug Interaction Potentiation
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05558150
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05509543
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
- Conditions
- Drug Interaction Potentiation
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05237297
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 277
- Registration Number
- NCT03444883
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Busanjin-gu, Korea, Republic of
🇰🇷Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Jongno-gu, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Livzon Pharmaceutical Group Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT03362268
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
- Conditions
- Peptic Ulcer Hemorrhage
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Livzon Pharmaceutical Group Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT03362281
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.